Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway Corrigendum in /10.3892/ijo.2024.5635

Song,Mingzhi; Tian,Xiliang; Lu,Ming; Zhang,Xianbin; Ma,Kai; Lv,Zhichao; Wang,Zhenxing; Hu,Yang; Xun,Chong; Zhang,Zhen; Wang,Shouyu

doi:10.3892/ijo.2015.2829

Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway

Corrigendum in: /10.3892/ijo.2024.5635

Authors:
- Mingzhi Song
- Xiliang Tian
- Ming Lu
- Xianbin Zhang
- Kai Ma
- Zhichao Lv
- Zhenxing Wang
- Yang Hu
- Chong Xun
- Zhen Zhang
- Shouyu Wang
View Affiliations

Affiliations: Department of Orthopaedics, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: January 9, 2015 https://doi.org/10.3892/ijo.2015.2829
Pages: 1131-1140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The peroxisome proliferator-activated receptor γ (PPARγ) is emerging as an important regulator in various metabolic processes of cancer. Genistein, as a major isoflavonoid isolated from dietary soybean, possesses a wide variety of biological activities, particularly, in cancer prevention. However, the mechanisms by which genistein elicits its growth inhibiting effects in osteosarcoma (OS) MG-63 cells have not been extensively elucidated. MG-63 cells were treated for 2 days with various concentrations of genistein and/or GW9662 (a selective antagonist of PPARγ). The effect of different drugs on cell viability was determined by Cell Counting Kit-8 (CCK-8). The assay of cell proliferation was performed using 5-ethynyl-2'-deoxyuridine (EdU). The changes of apoptosis and cell cycle progression were detected by flow cytometry experiments. The protein expression of PPARγ pathway (PPARγ, PTEN, BCL-2, Survivin, P21WAF1/CIP1 and Cyclin B1) was determined by western blot analysis. The expression of PPARγ and PTEN mRNA was detected by real-time quantitative RT-PCR analysis. We report that genistein caused OS cell growth inhibition. We found that the PPARγ expression in OS cells increased after genistein treatment. Further studies on the mechanisms of genistein revealed a series of cell growth changes related to the PPARγ pathway; while cell cycle changes can be reversed by GW9662. Genistein plays an important role in preventing OS cell growth, which can impede the OS cell cycle as a non-toxic activator of PPARγ, providing novel insights into the mechanisms of the therapeutic activities of genistein.

View Figures

View References

1	Yang Z, Kulkarni K, Zhu W, et al: Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem. 10:1264–1280. 2012. View Article : Google Scholar
2	Banerjee S, Li Y, Wang Z, et al: Multi-targeted therapy of cancer by genistein. Cancer Lett. 2:226–242. 2008. View Article : Google Scholar
3	Zhang Z, Wang CZ, Du GJ, et al: Genistein induces G2/M cell cycle arrest and apoptosis via atm/p53-dependent pathway in human colon cancer cell. Int J Oncol. 1:289–296. 2013.
4	Ullah MF, Ahmad A, Zubair H, et al: Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol Nutr Food Res. 4:553–559. 2011. View Article : Google Scholar
5	Mizushina Y, Shiomi K, Kuriyama I, et al: Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cancer cell proliferation. Int J Oncol. 4:1117–1124. 2013.
6	Hwang KA, Kang NH, Yi BR, et al: Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by 17beta-estradiol or bisphenol A via the inhibition of cell cycle progression. Int J Oncol. 2:733–740. 2013.
7	Xia J, Cheng L, Mei C, et al: Genistein inhibits cell growth and invasion through regulation of mir-27a in pancreatic cancer cells. Curr Pharm Des. 33:5348–5353. 2014. View Article : Google Scholar
8	Hilakivi-Clarke L, Onojafe I, Raygada M, et al: Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer. 11:16821999. View Article : Google Scholar
9	Zhou JR, Mukherjee P, Gugger ET, et al: Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res. 22:5231–5238. 1998.
10	Li C, Teng RH, Tsai YC, et al: H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br J Cancer. 1:80–88. 2004.
11	Yang CH, Murti A, Pfeffer SR, et al: Interferon α/β promotes cell survival by activating nuclear factor κB through phosphatidylinositol 3-kinase and Akt. J Biol Chem. 17:13756–13761. 2001.
12	Yamashita K, Suzuki M, Iwata H, et al: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases. FEBS Lett. 1:103–107. 1996. View Article : Google Scholar
13	Nikitovic D, Tsatsakis AM, Karamanos NK, et al: The effects of genistein on the synthesis and distribution of glycosaminoglycans/proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res. 23(1A): 459–464. 2003.PubMed/NCBI
14	Morris C, Thorpe J, Ambrosio L, et al: The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J Nutr. 5:1166–1170. 2006.
15	Zhang B, Shi ZL, Liu B, et al: Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-κB. Anticancer Drugs. 3:288–296. 2010. View Article : Google Scholar
16	Liang C, Li H, Shen C, et al: Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-kappaB pathway. Anticancer Agents Med Chem. 5:554–563. 2012. View Article : Google Scholar
17	Nakamura A, Aizawa J, Sakayama K, et al: Genistein inhibits cell invasion and motility by inducing cell differentiation in murine osteosarcoma cell line LM8. BMC Cell Biol. 1:242012. View Article : Google Scholar
18	Rickard DJ, Monroe DG, Ruesink TJ, et al: Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem. 3:633–646. 2003. View Article : Google Scholar
19	Salvatori L, Caporuscio F, Coroniti G, et al: Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol. 1:35–44. 2009. View Article : Google Scholar
20	Djiogue S, Njamen D, Halabalaki M, et al: Estrogenic properties of naturally occurring prenylated isoflavones in U2OS human osteosarcoma cells: Structure-activity relationships. J Steroid Biochem Mol Biol. 4–5:184–191. 2010. View Article : Google Scholar
21	Nakamura H, Wang Y, Kurita T, et al: Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS One. 5:e200342011. View Article : Google Scholar
22	Dang ZC, Audinot V, Papapoulos SE, et al: Peroxisome proliferator-activated receptor gamma as a molecular target for the soy phytoestrogen genistein. J Biol Chem. 2:962–967. 2003. View Article : Google Scholar
23	Mezei O, Banz WJ, Steger RW, et al: Soy isoflavones exert anti-diabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 5:1238–1243. 2003.
24	Xiang Q, Lin G, Fu X, et al: The role of peroxisome proliferator-activated receptor-γ and estrogen receptors in genistein-induced regulation of vascular tone in female rat aortas. Pharmacology. 2:117–124. 2010. View Article : Google Scholar
25	Youssef J and Badr M: Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 1:68–82. 2011. View Article : Google Scholar
26	Willson TM, Lambert MH and Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 70:341–367. 2001. View Article : Google Scholar : PubMed/NCBI
27	Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI
28	Bundscherer A, Reichle A, Hafner C, et al: Targeting the tumor stroma with peroxisome proliferator activated receptor agonists. Anticancer Agents Med Chem. 7:816–821. 2009. View Article : Google Scholar
29	Rumi MA, Ishihara S, Kazumori H, et al: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents. 6:465–477. 2004. View Article : Google Scholar
30	Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 1:237–241. 1997. View Article : Google Scholar
31	Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 15:3344–3352. 1998.
32	Asou H, Verbeek W, Williamson E, et al: Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol. 5:1027–1031. 1999.
33	Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 1:75–80. 1999. View Article : Google Scholar
34	Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 15:8806–8811. 1998. View Article : Google Scholar
35	Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 3:465–470. 1998. View Article : Google Scholar
36	Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 4:1129–1138. 2000.
37	Ali AA, Weinstein RS, Stewart SA, et al: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 3:1226–1235. 2005. View Article : Google Scholar
38	Rzonca SO, Suva LJ, Gaddy D, et al: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 1:401–406. 2004. View Article : Google Scholar
39	Rajkumar T and Yamuna M: Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs. 3:257–265. 2008. View Article : Google Scholar
40	Yamaguchi K, Whitlock NC, Liggett JL, et al: Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene. Vet J. 1:89–95. 2008. View Article : Google Scholar
41	He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res. 8:2235–2245. 2010. View Article : Google Scholar
42	Haydon RC, Luu HH and He TC: Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 454:237–246. 2007. View Article : Google Scholar
43	Haydon RC, Zhou L, Feng T, et al: Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 5:1288–1294. 2002.
44	Yu LX, Yan HX, Liu Q, et al: Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology. 4:1322–1333. 2010. View Article : Google Scholar
45	Lv L, Xiao XY, Gu ZH, et al: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 1–2:11–21. 2011. View Article : Google Scholar
46	Lu Q, Lu S, Gao X, et al: Norisoboldine, an alkaloid compound isolated from Radix Linderae, inhibits synovial angiogenesis in adjuvant-induced arthritis rats by moderating Notch1 pathway-related endothelial tip cell phenotype. Exp Biol Med. 8:919–932. 2012. View Article : Google Scholar
47	Seargent JM, Yates EA and Gill JH: GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 8:933–937. 2004. View Article : Google Scholar
48	Patel L, Pass I, Coxon P, et al: Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 10:764–768. 2001. View Article : Google Scholar
49	Wu ZX, Song TB, Li DM, et al: Overexpression of PTEN suppresses growth and induces apoptosis by inhibiting the expression of survivin in bladder cancer cells. Tumour Biol. 1:9–15. 2007. View Article : Google Scholar
50	Mikhail M, Velazquez E, Shapiro R, et al: PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 14:5153–5157. 2005. View Article : Google Scholar
51	Raffoul JJ, Wang Y, Kucuk O, et al: Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer. 6:1072006. View Article : Google Scholar : PubMed/NCBI
52	Ouyang G, Yao L, Ruan K, et al: Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int. 12:1237–1244. 2009. View Article : Google Scholar
53	Wagner ER, He BC, Chen L, et al: Therapeutic implications of PPARgamma in human osteosarcoma. PPAR Res. 9564272010.PubMed/NCBI
54	Miao J, Wu S, Peng Z, et al: MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 4:2093–2098. 2013. View Article : Google Scholar
55	Weng L, Brown J and Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet. 3:237–242. 2001. View Article : Google Scholar
56	Waite KA, Sinden MR and Eng C: Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet. 11:1457–1463. 2005. View Article : Google Scholar
57	Choi YH, Lee WH, Park KY, et al: p53-independent induction of p21, reduction of Cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res. 2:164–173. 2000. View Article : Google Scholar
58	Mayo LD and Donner DB: The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 9:462–467. 2002. View Article : Google Scholar
59	Zhang T, Wang F, Xu H-X, et al: Activation of nuclear factor erythroid 2-related factor 2 and PPARγ plays a role in the genis-tein-mediated attenuation of oxidative stress-induced endothelial cell injury. Br J Nutr. 2:223–235. 2013. View Article : Google Scholar
60	Halasova E, Adamkov M, Matakova T, et al: Expression of Ki-67, Bcl-2, survivin and p53 proteins in patients with pulmonary carcinoma. Adv Exp Med Biol. 756:15–21. 2013. View Article : Google Scholar
61	Gao Q, Yang S and Kang MQ: Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Rep. 6:1409–1414. 2012.
62	Ma Y and Wang HS: Correlations of Bcl-2 and survivin gene protein expressions in colorectal cancer. Applied Mech Mater. 423–426:362–365. 2013. View Article : Google Scholar
63	Kumar P, Miller AI and Polverini PJ: p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem. 41:43352–43360. 2004. View Article : Google Scholar
64	Fong WH, Tsai HD, Chen YC, et al: Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol. 2–3:180–186. 2010. View Article : Google Scholar
65	Ren Y, Sun C, Sun Y, et al: PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol. 2–3:169–174. 2009. View Article : Google Scholar
66	Kim YJ, Park KJ, Song JK, et al: The PPARgamma agonist protects cardiomyocytes from oxidative stress and apoptosis via thioredoxin overexpression. Biosci Biotechnol Biochem. 12:2181–2187. 2012. View Article : Google Scholar